Phase 3 Clinical Data on Investigational mRNA Therapy Presented at ESMO Congress
What happened
Researchers presented Phase 3 clinical data at the European Society for Medical Oncology Congress on September 21, 2026. The presentations included a Presidential Symposium led by Georgina V. Long regarding the Phase 3 study of intismeran autogene combined with pembrolizumab for adjuvant treatment of resected stage IIB-IV melanoma. Additionally, David J. Pinato presented findings from a Phase I study on adjuvant intismeran autogene combined with FOLFIRINOX for pancreatic ductal adenocarcinoma.
From pr-inside.com
Why it matters
The presentations concern intismeran autogene, an investigational mRNA-based individualized neoantigen therapy. The findings are relevant to the ongoing development pipeline of Moderna, which is involved in the research. The data could influence future regulatory pathways for advanced cancer treatments.
From pr-inside.com
Who's involved
- European Society for Medical OncologyProfessional organization hosting the presentations
- ModernaCompany presenting research findings at the congress
- Georgina V. LongResearcher leading the Presidential Symposium on Phase 3 data
- David J. PinatoMedical oncologist presenting on adjuvant cancer treatment
- Charu AggarwalPulmonary oncologist whose data was presented at the congress
How this reaches others
Each traced step by step, with the reporting behind itKeep exploring
The entities involved
-
European Society for Medical Oncology
Professional organisation
Nothing else this week.
-
Charu Aggarwal
American pulmonary oncologist
Nothing else this week.